 |
Journal articles
Ultrafast and whole-body cooling with total liquid ventilation induces favorable neurological and cardiac outcomes after cardiac arrest in rabbits.: Liquid ventilation, hypothermia and cardiac arrest
Abstract : Background- In animal models of cardiac arrest, the benefit afforded by hypothermia is closely linked to the rapidity of the decrease in body temperature after resuscitation. Because total liquid ventilation (TLV) with temperature-controlled perfluorocarbons induces a very rapid and generalized cooling, we aimed to determine whether this could limit the post-cardiac arrest syndrome in a rabbit model. We especially focused on neurological, cardiac, pulmonary, liver and kidney dysfunctions. Methods and Results- Anesthetized rabbits were submitted to either 5 or 10 minutes of untreated ventricular fibrillation. After cardiopulmonary resuscitation and resumption of a spontaneous circulation, the animals underwent either normothermic life support (control) or therapeutic hypothermia induced by TLV. The latter procedure decreased esophageal and tympanic temperatures to 32°C to 33°C within only 10 minutes. After rewarming, the animals submitted to TLV exhibited an attenuated neurological dysfunction and decreased mortality 7 days later compared with control. The neuroprotective effect of TLV was confirmed by a significant reduction in brain histological damages. We also observed limitation of myocardial necrosis, along with a decrease in troponin I release and a reduced myocardial caspase 3 activity, with TLV. The beneficial effects of TLV were directly related to the rapidity of hypothermia induction because neither conventional cooling (cold saline infusion plus external cooling) nor normothermic TLV elicited a similar protection. Conclusions- Ultrafast cooling instituted by TLV exerts potent neurological and cardiac protection in an experimental model of cardiac arrest in rabbits. This could be a relevant approach to provide a global and protective hypothermia against the post-cardiac arrest syndrome.
https://www.hal.inserm.fr/inserm-00623259
Contributor : Georges Guellaen <>
Submitted on : Tuesday, March 13, 2012 - 7:00:08 AM
Last modification on : Thursday, May 27, 2021 - 5:08:02 PM
Long-term archiving on: : Thursday, June 14, 2012 - 4:26:51 PM
Contributor : Georges Guellaen <>
Submitted on : Tuesday, March 13, 2012 - 7:00:08 AM
Last modification on : Thursday, May 27, 2021 - 5:08:02 PM
Long-term archiving on: : Thursday, June 14, 2012 - 4:26:51 PM
Files
Manuscipt_Accepted.pdf
Files produced by the author(s)
- clinical_summary.pdf Files produced by the author(s)
- inserm-00623259_edited.pdf Files produced by the author(s)